Allarity Therapeutics is advancing its drug approval process, supported by AACR data and a new USPTO patent.
1 report, 1 independent
Updated Aug 14
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Allarity Therapeutics is advancing its drug approval process, supported by AACR data and a new USPTO patent.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
American Association for Cancer Research
scientific society
Nothing else this week.
Related events
- An AI-designed drug is currently in trials, prompting a focus on global legal and ethical standards.
- Adam Craig reported positive results that could support FDA approval for a treatment.
- FDA placed a clinical hold on the drug application submitted by Bright Minds Biosciences Inc.
- FDA granted approvals for RASONQUE and WELTRUZA on November 4, 2026.
- ADC Therapeutics received accelerated approval for its drug from the FDA.